Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Epsin-3 is a member of the epsin family of highly conserved membrane-associated endocytic adaptor proteins. It is characterized by an N-terminal ENTH (Epsin N-Terminal Homology) domain that binds phosphatidylinositol (4,5)-bisphosphate and contributes to the initiation of clathrin-coated vesicle formation through membrane curvature induction. Unlike other epsins, Epsin-3 displays highly regulated expression and is induced in human keratinocytes migrating over type I collagen, such as during cutaneous wound healing; it is not detectable in healthy, differentiated skin. Epsin-3 is implicated in the coordination of endocytosis and signal transduction, acting as an adaptor that helps recruit ubiquitinated cargo to the clathrin-mediated endocytic machinery and interacts with Rho GTPase-regulatory proteins, linking cell signaling and polarity with membrane trafficking. Upregulation of Epsin-3 has been observed in epithelial pathologies and several cancer types, where it is thought to enhance cell migration and invasion, making it a candidate biomarker and a potential therapeutic target in oncology. Currently, no direct drug interactions or approved targeted therapies are known for Epsin-3.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Epsin-3 (EPN3).